Oriol Juanola, Paula Piñero, Isabel Gómez‐Hurtado, Esther Caparrós, Rocío García‐Villalba, Alicia Marín, Pedro Zapater, Fabián Tarín, José M. González‐Navajas, Francisco A. Tomás‐Barberán, Rubén Francés – 22 October 2018 – Intestinal permeability to translocation of bacterial products is increased in cirrhosis. Regulatory T cells (Tregs) remain central to the interplay between the host and microbial milieu. We propose that Tregs are involved in promoting gut barrier integrity and a balanced interaction with gut microbiota–derived short‐chain fatty acids (SCFAs).

Mauro Bernardi, Giacomo Zaccherini, Paolo Caraceni – 22 October 2018 – The wait‐list mortality of patients with decompensated cirrhosis awaiting liver transplantation remains elevated due to the occurrence of complications. Etiologic treatments improve patient survival and lower the incidence of complications when applied in compensated cirrhosis, but a decompensated disease does not improve or even progress despite a response to therapy in a substantial number of patients. Thus, disease‐modifying treatments that reduce the incidence of complications and improve survival are most needed.

Joseph M. G. V. Gassner, Maximilian Nösser, Simon Moosburner, Rosa Horner, Peter Tang, Lara Wegener, David Wyrwal, Felix Claussen, Ruza Arsenic, Johann Pratschke, Igor M. Sauer, Nathanael Raschzok – 20 October 2018 – Normothermic ex vivo liver machine perfusion might be a superior preservation strategy for liver grafts from extended criteria donors. However, standardized small animal models are not available for basic research on machine perfusion of liver grafts.

Jinhua Yan, Bin Yao, Hongyu Kuang, Xubin Yang, Qin Huang, Tianpei Hong, Yushu Li, Jingtao Dou, Wenying Yang, Guijun Qin, Huijuan Yuan, Xinhua Xiao, Sihui Luo, Zhongyan Shan, Hongrong Deng, Ying Tan, Fen Xu, Wen Xu, Longyi Zeng, Zhuang Kang, Jianping Weng – 19 October 2018 – To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add‐on liraglutide, sitagliptin, or insulin glargine in this 26‐w

Jinhua Yan, Bin Yao, Hongyu Kuang, Xubin Yang, Qin Huang, Tianpei Hong, Yushu Li, Jingtao Dou, Wenying Yang, Guijun Qin, Huijuan Yuan, Xinhua Xiao, Sihui Luo, Zhongyan Shan, Hongrong Deng, Ying Tan, Fen Xu, Wen Xu, Longyi Zeng, Zhuang Kang, Jianping Weng – 19 October 2018 – To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add‐on liraglutide, sitagliptin, or insulin glargine in this 26‐w

Sumeet K. Asrani, Linda W. Jennings, James F. Trotter, Josh Levitsky, Mitra K. Nadim, W.R. Kim, Stevan A. Gonzalez, Bernard Fischbach, Ranjeeta Bahirwani, Michael Emmett, Goran Klintmalm – 19 October 2018 – Estimation of glomerular filtration rate (eGFR) in patients with liver disease is suboptimal in the presence of renal dysfunction. We developed a model for GFR assessment in liver disease (GRAIL) before and after liver transplantation (LT).

Alberto Larghi, Andrea Tringali, Mihai Rimbaş, Federico Barbaro, Vincenzo Perri, Gianenrico Rizzatti, Antonio Gasbarrini, Guido Costamagna – 17 October 2018 – Biliary strictures represent some of the most frequent complications encountered after orthotopic liver transplantation. They comprise an array of biliary abnormalities with variations in anatomical location, clinical presentation, and different pathogenesis.

Magdalena Meszaros, Valérie Dubois, Matthias Niemann, Jose Ursic‐Bedoya, Stéphanie Faure, Olivier Guillaud, Olivier Boillot, Georges‐Philippe Pageaux, Céline Thevenin, Jérôme Dumortier – 17 October 2018

Elzbieta Kolaczkowska, Craig N. Jenne – 17 October 2018

Yongyan Chen, Xiaolei Hao, Rui Sun, Haiming Wei, Zhigang Tian – 17 October 2018 – Hepatitis B virus (HBV) is a major risk factor for development of hepatocellular carcinoma (HCC), at least partially due to dysfunctional anti‐HBV adaptive immunity; however, the role of innate immune response to HBV in this process is not well understood.